- In study, test proved able to detect and localize more than 20 types of cancer with a high degree of accuracy
- Test detected methylation patterns associated with cancer in free-floating DNA in blood
A new blood test in development has shown ability to screen for numerous types of cancer with a high degree of accuracy, a trial of the test shows. Dana-Farber Cancer Institute investigators will present the results of the multi-center trial during a session today at the European Society for Medical Oncology (ESMO) 2019 Congress.
The test, developed by GRAIL, Inc., uses next-generation sequencing technology to probe DNA for tiny chemical tags (methylation) that influence whether genes are active or inactive. When applied to nearly 3,600 blood samples – some from patients with cancer, some from people who had not been diagnosed with cancer at the time of the blood draw – the test successfully picked up a cancer signal from the cancer patient samples, and correctly identified the tissue from where the cancer began (the tissue of origin). The test’s specificity – its ability to return a positive result only when cancer is actually present – was high, as was its ability to pinpoint the organ or tissue of origin, researchers found.
The new test looks for DNA, which cancer cells shed into the bloodstream when they die. In contrast to “liquid biopsies,” which detect genetic mutations or other cancer-related alterations in DNA, the technology focuses on modifications to DNA known as methyl groups. Methyl groups are chemical units that can be attached to DNA, in a process called methylation, to control which genes are “on” and which are “off.” Abnormal patterns of methylation turn out to be, in many cases, more indicative of cancer – and cancer type – than mutations are. The new test zeroes in on portions of the genome where abnormal methylation patterns are found in cancer cells.
“Our previous work indicated that methylation-based assays outperform traditional DNA-sequencing approaches to detecting multiple forms of cancer in blood samples,” said the study’s lead author, Geoffrey Oxnard, MD, of Dana-Farber. “The results of the new study demonstrate that such assays are a feasible way of screening people for cancer.”
In the study, investigators analyzed cell-free DNA (DNA that had once been confined to cells but had entered the bloodstream upon the cells’ death) in 3,583 blood samples, including 1,530 from patients diagnosed with cancer and 2,053 from people without cancer. The patient samples comprised more than 20 types of cancer, including hormone receptor-negative breast, colorectal, esophageal, gallbladder, gastric, head and neck, lung, lymphoid leukemia, multiple myeloma, ovarian, and pancreatic cancer.
The overall specificity was 99.4%, meaning only 0.6% of the results incorrectly indicated that cancer was present. The sensitivity of the assay for detecting a pre-specified high mortality cancers (the percent of blood samples from these patients that tested positive for cancer) was 76%. Within this group, the sensitivity was 32% for patients with stage I cancer; 76% for those with stage II; 85% for stage III; and 93% for stage IV. Sensitivity across all cancer types was 55%, with similar increases in detection by stage. For the 97% of samples that returned a tissue of origin result, the test correctly identified the organ or tissue of origin in 89% of cases.
Detecting even a modest percent of common cancers early could translate into many patients who may be able to receive more effective treatment if the test were in wide use, Oxnard remarked.
The Latest on: Blood test for cancer
via Google News
The Latest on: Blood test for cancer
- A Call to Test Men With Prostate Cancer for COVID-19on August 7, 2020 at 8:14 am
A team of New York City urologists proposes that men with prostate cancer get tested for COVID-19 because of their vulnerabilities to the infection.
- Cancer blood test developer Guardant Health signs Silicon Valley's largest office lease of 2020on August 7, 2020 at 4:39 am
Liquid biopsy company Guardant Health Inc. — fresh from raising a multi-million-dollar stock offering — has agreed to lease nearly 250,000 square feet at the former Hewlett Packard Enterprise Co. (HPE ...
- Cleveland Clinic studying blood test that detects more than 50 cancerson August 6, 2020 at 11:35 am
The Cleveland Clinic is taking part in a new study focused on a test with the ability to detect more than 50 cancers with a single blood draw. Officials say the PATHFINDER study plans to enroll ...
- Cleveland Clinic Joins Interventional Study Using GRAIL’s Multi-Cancer Early Detection Test to Help Guide Clinical Careon August 6, 2020 at 6:00 am
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, announced today that Cleveland Clinic has joined GRAIL’s PATHFINDER Study, ...
- Sysmex-Inostics Colorectal Cancer Blood-Based OncoBEAMTM RAS CE-IVD Test Shows Concordance with Standard of Care Tissue-Based RAS Testingon August 5, 2020 at 3:06 am
Sysmex-Inostics, Inc., a global leader and pioneer in blood-based circulating tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study evaluating the performance of ...
- A blood test may be an easy way to predict who will benefit from immunotherapyon August 3, 2020 at 3:48 pm
A test which detects changing levels of tumour fragments in the blood may be an easy, non-invasive and quick way to predict who will benefit from immunotherapy, a treatment option for advanced cancers ...
- A blood test could predict who benefits from immunotherapyon August 3, 2020 at 9:42 am
A test which detects changing levels of tumor fragments in the blood may be an easy, non-invasive and quick way to predict who will benefit from immunotherapy, a treatment option for advanced cancers.
- Pathnova Laboratories (PATHNOVA) Enters into Partnership to Commercialize Todos Medicals COVID-19 and Breast Cancer Tests in Singaporeon August 3, 2020 at 4:00 am
Temasek Life Sciences Accelerator-backed PATHNOVA to Offer COVID-19 Testing Kits Supplied by Todos in Singapore and Southeast Asia. REHOVOT, Israel, SINGAPORE and NEW YORK, NY ...
- New blood test can detect prostate cancer and confirm the stage of the diseaseon July 30, 2020 at 12:52 am
A new blood test developed by scientists and clinicians is able to detect the presence of prostate cancer and confirm how advanced it is.
- Experimental Blood Test Detects Cancer Years Before Symptomson July 29, 2020 at 8:03 am
An experimental blood test was able to detect 5 different tumor types up to four years before patients were diagnosed with cancer.
via Bing News